RNA编辑
核糖核酸
RNA沉默
生物
阿达尔
肌苷
RNA剪接
内含子
转录后修饰
非编码RNA
鸟苷
遗传学
生物化学
腺苷
RNA干扰
基因
作者
Wei Liang Gan,Larry Ng,Bryan Yik Loong Ng,Leilei Chen
出处
期刊:Cancer treatment and research
日期:2023-01-01
卷期号:: 143-179
被引量:2
标识
DOI:10.1007/978-3-031-45654-1_5
摘要
RNA epigenetics, or epitranscriptome, is a growing group of RNA modifications historically classified into two categories: RNA editing and RNA modification. RNA editing is usually understood as post-transcriptional RNA processing (except capping, splicing and polyadenylation) that changes the RNA nucleotide sequence encoded by the genome. This processing can be achieved through the insertion or deletion of nucleotides or deamination of nucleobases, generating either standard nucleotides such as uridine (U) or the rare nucleotide inosine (I). Adenosine-to-inosine (A-to-I) RNA editing is the most prevalent type of RNA modification in mammals and is catalyzed by adenosine deaminase acting on the RNA (ADAR) family of enzymes that recognize double-stranded RNAs (dsRNAs). Inosine mimics guanosine (G) in base pairing with cytidine (C), thereby A-to-I RNA editing alters dsRNA secondary structure. Inosine is also recognized as guanosine by the splicing and translation machineries, resulting in mRNA alternative splicing and protein recoding. Therefore, A-to-I RNA editing is an important mechanism that causes and regulates "RNA mutations" in both normal physiology and diseases including cancer. In this chapter, we reviewed current paradigms and developments in the field of A-to-I RNA editing in the context of cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI